Phasebio Pharmaceuticals Inc
SEC CIK 1169245 · PHAS · last insider filing 2023-05-19
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Harrigan Edmund | Director | filed 2018 - 2023 |
| Loewy Caroline M | Director | filed 2018 - 2023 |
| Hutson Nancy J | Director | filed 2018 - 2023 |
| van den Broek Richard | Director | filed 2019 - 2023 |
| Thorp Clay | Director | filed 2018 - 2023 |
| Humphries William D. | Director | filed 2021 - 2023 |
| Sapir Alex | Director | filed 2020 - 2023 |
| Mow Jonathan P | Director · Chief Executive Officer | filed 2018 - 2022 |
| Klein Peter Justin | Director | filed 2018 - 2021 |
| Mukhopadhyay Bibhash | Director | filed 2018 - 2019 |
| Tufts Linda | Director | filed 2018 - 2019 |
| Rivers Tyrell | Director | filed 2018 - 2018 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Sharp John P | Chief Financial Officer | filed 2018 - 2022 |
| Arnold Susan Elizabeth | VP, Preclinical and Chem. | filed 2018 - 2022 |
| Hanson Kristopher | Vice President, Head of Legal | filed 2019 - 2022 |
| Burkhardt Glen | VP, Human Resources | filed 2020 - 2022 |
| Birchall Jonathan | Chief Commercial Officer | filed 2021 - 2022 |
| Lee John Sang | Chief Medical Officer | filed 2018 - 2022 |
| York Michael | VP, Corporate Development | filed 2018 - 2021 |
| Ballance David James | VP, Research and Sci. Affairs | filed 2018 - 2020 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.